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individuals during 2004-2008 were used in this retrospective database study of
patients with metastatic or recurrent, locally-advanced HNC. Patients diagnosed
with HNCwerematched 1:1 to cancer-free control patients in order tomeasure the
incremental economic burden of metastatic and recurrent, locally-advanced HNC.
Outcomes of interest were measured during the 6 months following 1) date of a
secondary tumor diagnosis for metastatic patients, or 2) date of a diagnosis indi-
cating recurrent, locally-advanced HNC. The multivariable comparison of health-
care utilization rates was based on a logistic regressionmodel. Costs were reported
in 2008 US dollars from the perspective of a third-party payer and were analyzed
using generalized linear models and two-part regressionmodels. Regressionmod-
els were adjusted for age and baseline Charlson Comorbidity Index (excluding
cancer diagnoses) differences between HNC and control patients. RESULTS: The
metastatic HNC cohort consisted of 1,042 patients; the cohort of recurrent, locally-
advanced HNC included 324 patients. Compared to cancer-free patients, a higher
proportion of metastatic HNC patients had  1claim for inpatient (OR26.4), out-
patient (OR35.3), and ER visits (OR4.4). Recurrent, locally-advanced HNC pa-
tients also hadhigher utilization rates for inpatient (OR4.7) and ER visits (OR4.9).
All differences were statistically significant (p0.0001). Incremental adjusted total
costs were $60,414 per patient for metastatic HNC and $21,141 per patient for
recurrent, locally-advanced HNC (p0.0001). Approximately 46-58% of the incre-
mental cost was attributable to outpatient visits, 27-37% to inpatient costs, and
11-13% to pharmacy, depending on the cohort. CONCLUSIONS: Healthcare re-
source utilization and economic burden of patients with metastatic or recurrent,
locally-advanced HNC is substantial compared to cancer-free patients.
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OBJECTIVES: Dosing schedules for the erythropoiesis-stimulating agents (ESAs),
darbepoetin alfa (DA) and epoetin alfa (EA), differ with the availability of Q3W
dosing for DA compared to the predominantly weekly schedule for EA. For chemo-
therapy regimens with longer intervals between administrations, DA can be ad-
ministered less frequently than EA and presumably with a higher likelihood of
synchronization between chemotherapy and ESA schedules. This study examined
frequency of ESA visits and synchronization of chemotherapy and ESA adminis-
trations in current clinical practice. METHODS: A retrospective analysis of ESAs
utilization during ESA Episodes of Care (ESA EOCs) was conducted on all cancer
patients undergoing chemotherapy and receiving ESA therapy between 7/1/2007 to
3/31/2010 (n9,961). Patientswere identified in the SDI oncology electronicmedical
records database. ESA administrations were classified as synchronized with che-
motherapy-i.e. either received on the same day-or unsynchronized. The odds that
an ESA visit was synchronized with chemotherapy was compared for patients
receiving DA and EA using generalized estimating equations (GEE). Mean health-
care visits were compared usingHeckman’s 2-step estimator to overcome the sam-
ple selection bias. RESULTS: The numbers of patients by ESAwere 6,522 for DA and
3,439 for EA. The overall synchronization was higher for the DA (DA67% &
EA58%; p0.0001). The odds that an ESA administration was synchronized with
chemotherapy was higher for DA compared to EA (OR1.46, 95%CI: 1.37-1.54). DA
patients had 2.3 fewer visits with an ESA administration (p0.0001), and 3.0 fewer
total visits over the ESA EOC (p0.0001). CONCLUSIONS: Patients receiving DA
were more likely to have an ESA administration on the same healthcare visit as
chemotherapy and had fewer visits for ESA administrations compared to EA. This
evidence suggests that DAmay reduce patient and practice burden through greater
synchronization of ESA and chemotherapy administrations andmay reduce health
care utilization compared to EA.
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OBJECTIVES:Monoclonal antibody (mAb) therapies for the treatment ofmetastatic
colorectal cancer (mCRC) are associated with a risk of infusion reactions, though
the rates of infusion reactions differ among mAbs. Currently there is limited pub-
lished data on the clinical and economic impact of infusion reactions. The objective
of this studywas to investigate the resource use associatedwith infusion reactions
and the impact of these reactions on patient management in real-world clinical
practice in Europe.METHODS: Eighty oncologists and nurses from eight European
countries (Denmark, France, Germany, Greece, Italy, Spain, Sweden and the UK)
were interviewed by telephone over a 6-week period in 2010. To be included, the
respondents (10 from each country) must be currently treating patients with
mCRC. Each telephone interview lasted 30-45 minutes using a questionnaire (16
questions) specifically developed for this study. RESULTS: The mean number of
total staff (including physicians and nurses) involved in managing an infusion
reactionwas 1.97 for a grade 1 infusion reaction, 2.35 for a grade 2 infusion reaction,
3.60 for a grade 3 infusion reaction and 5.30 for a grade 4 infusion reaction. For
grade 3 infusion reactions, the majority of patients (73.4%) were treated in a hos-
pital inpatient setting; while for grade 4 infusion reactions, themajority of patients
(82.5%) were treated in intensive care. Treatment duration in hospitals for infusion
reactions also increased with the severity. Among patients hospitalized for infu-
sion reactions, grade 3 infusion reactions were treated for a mean of half day (13.3
( 29) hours) in intensive care compared to amean of 2 days (48.1 ( 43.7) hours) for
grade 4 infusion reactions. CONCLUSIONS: In conclusion, infusion reactions led to
substantial resource use, which increased with the severity of the infusion reac-
tions in real-world clinical practice across eight European countries.
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OBJECTIVES: Monoclonal antibody treatments for metastatic colorectal cancer
(mCRC) have different treatment-related toxicities. This study aimed to elucidate
the hospitalisation costs of adverse events (AEs) commonly associated withmono-
clonal antibodies when administered to patients with mCRC. METHODS: This
study extracted data for patients newly diagnosed with mCRC from a large US
claims database from January 2005 to June 2008. The first distant metastasis diag-
nosis date was defined as the index date. Hospital admissions for AEs of interest
were identified by primary discharge diagnoses after the index date. Main out-
comes weremean length of hospital stay (days) and hospitalisation costs (US$) per
hospital admission for AEs identified. All analyses are presented descriptively.
RESULTS: The study population (aged 18 years; n12,648) was balanced accord-
ing to gender and was mainly aged 50 years or older (90.1%). Most patients had
colon cancer (70.1%) as opposed to rectal cancer. The longestmean (median) length
of stay was observed forWound-healing complications (14.1 (7.0) days) and gastro-
intestinal (GI) perforation (13.8 (11.5) days), followed by hypertension (8.5 (3.0)
days), arterial thromboembolism (7.1 (5.5) days), venous thromboembolism (5.4
(4.0) days), and congestive heart failure (5.3 (4.0) days). The highest inpatient cost
per event was for GI perforations (mean $66,224 and median $34,027), followed by
arterial thromboembolism (mean $40,992 and median $18,587), wound-healing
complications (mean $36,440 and median $21,163), interstitial lung disease (mean
$26,705 and median $19,111), and acute myocardial infarction (mean $22,395 and
median $15,223). Skin toxicity (mean $6,475 and median $6110) was associated
with relatively low costs. CONCLUSIONS: Hospital costs for monoclonal antibody
treatment-related AEs in patients with mCRC vary greatly. This study provides
source data for economic evaluations of head-to-head comparisons of monoclonal
antibody treatments.
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OBJECTIVES: To estimate NICE’s cost effectiveness threshold following application
of its end-of-life supplemental advice criteria (EOL) to single technology appraisals
(STA) for cancer drugs.METHODS:We searched all NICE STAs for cancer drugs in
2009 and 2010 and identified 30 STAs for which EOL advice was given.We excluded
two STAs because the estimated ICER was less than NICE’s cost effectiveness
threshold value of £30,000. Each STA was evaluated on the extent to which NICE
deemed the drug to have satisfied each of the three EOL criteria. The ICER of each
drug that met all three EOL criteria was compared to the £30,000 threshold.
RESULTS: Two of the 28 drugs did not meet the first criterion that the treatment is
indicated for patients whose life expectancy is normally less than 24 months. Twelve drugs
did not meet the second criterion that there is sufficient evidence to indicate that the tech-
nology extends life by at least 3 months compared to current NHS treatments. Eight drugs
did not meet the third criterion that the treatment is indicated for small patient populations.
Four STAs only evaluated two of the three EOL criteria. In all, Appraisal Committees
considered 14 drugs to have satisfied the three EOL criteria, only six of which were
considered cost effective. The highest ICER for cost effective treatments was £47,000
and the lowest ICERwas £52,600 for the eight treatmentsnot considered cost effective.
CONCLUSIONS: It can be reasonably surmised that the cost effectiveness threshold
for EOL treatments is around £50,000. How EOL criteria are interpreted varies, how-
ever. The first criterion is straightforward, based largely onwidely accepted estimates
of life expectancy for the given indication. Robustness of survival data will dictate
application of the second criterion. Manufacturers should expect an estimated popu-
lation of 7,000 to satisfy the third criterion.
PCN106
RESEARCH ON THE FACTORS AFFECTING THE ADOPTION OF HIGH VALUE
MEDICAL CONSUMES IN LESS DEVELOPED AREAS OF CHINA
Jing W, Guanglian X
Huazhong University of Science and Technology, Wuhan, Hubei, China
OBJECTIVES: Taking stapler as an example, to explore the factors affection the
adoption of high value medical consumes in less developed areas of China.
METHODS: 714 medical records were selected from the prefecture-level and cou-
nty-level hospitals in Hubei, Henan, Sichuan and Shandong to collect information
and 117 relevant personnel were interviewed deeply. RESULTS: Drivers and Barri-
ers for Stapler Adoption Drivers: Strong perceived benefits and cost-effectiveness
among surgeons, hospital leaders; Hospitals and surgeons keen to adopt new tech-
nologies and techniques; General market development. Barriers: Prefecture Level:
No significant barrier to adoption; key issue is market share versus domestic; bar-
riers to share gain are surgeon loyalty to and moderate satisfaction with domestic
products, reimbursement policy. County Level: Patient affordability and surgeon
skills/awareness are both barriers, but our study design did not permit quantifica-
tion of their relative impacts. Decision-Making Unit and Influences: Surgical direc-
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